Results 91 to 100 of about 186,806 (295)

Treatable traits in chronic cough: a prospective evaluation for predicting cough persistence

open access: yesERJ Open Research
Background The concept of treatable traits has been proposed for managing chronic cough; however, evidence supporting its clinical utility remains limited.
Yeonhee Kim   +22 more
doaj   +1 more source

Mechanistic Insights Into Photocatalytic Materials for Toxic Pollutants: Environmental Remediation of Personal Care Products

open access: yesAsia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Photocatalytic materials have emerged as promising solutions for environmental applications due to their ability to degrade organic pollutants under sunlight or artificial light. In this review, recent progress on the photocatalytic materials used for the degradation of pharmaceutical personal care products (PPCPs) in environmental ...
Urvashi Sen   +5 more
wiley   +1 more source

Systematic literature review of treatments used for refractory or unexplained chronic cough in adults

open access: yesAnnals of Thoracic Medicine
BACKGROUND: Refractory or unexplained chronic cough (RCC or UCC) is difficult to manage and is usually treated by the off-label use of drugs approved for other indications.
Vishal Bali   +9 more
doaj   +1 more source

Efficacy of Gefapixant, a P2X3 Antagonist, for Refractory Atopic Cough

open access: yesInternational Medical Case Reports Journal, 2023
Yoshihisa Ishiura, Shosaku Nomura, Yuka Ishii, Kai Imai, Yusuke Sawai, Takeshi Tamaki, Toshiki Shimizu, Naoyuki Miyashita, Tomoki Ito First Department of Internal Medicine, Kansai Medical University, Osaka, JapanCorrespondence: Yoshihisa Ishiura, First ...
Ishiura Y   +8 more
doaj  

Chronic cough [PDF]

open access: yesThorax, 1999
C E BRIGHTLING   +7 more
openaire   +2 more sources

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Chronic cough

open access: yesInternational Journal of Clinical Practice, 1985
Sidney S. Braman, William M. Corrao
openaire   +3 more sources

Virtual healthcare compared to hospital care for acute and post‐acute illness in adults: A systematic review and meta‐analysis of randomized controlled trials

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the clinical effectiveness, cost‐effectiveness, quality of life (QoL) and patient/caregiver satisfaction associated with VWs/HaH vs. traditional inpatient care in adults with acute or post‐acute illness. Methods We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs), following PRISMA 2020 guidelines ...
Rana A. Malhis   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy